Skip to main content

Table 3 Implication of ECM in response to therapy for solid tumors

From: The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?

Cancer type Study model Treatment Effect on ECM component Reference
Lewis lung carcinoma In vitro—3D models Doxorubicin Diffusion of doxorubicin in tumor spheroids is hampered by the overexpression of LOX and LOXL2 [153]
Fibrosarcoma
Breast carcinoma
Pancreatic ductal adenocarcinoma In vivo—murine model Doxorubicin Hyaluronidases reduce the hyaluronic acid content and increase the uptake of gemcitabine and doxorubicin [156]
Osteosarcoma In vivo—murine model Liposomal doxorubicin Uptake of liposomal doxorubicin is improved by hyaluronidase treatment [157]
Small cell lung cancer In vitro—cell lines Etoposide Expression of survival signals through ILK/Akt/NFkB determines the interaction between fibronectin and integrin β1, protecting against etoposide [158]
Ovarian carcinoma In vitro—cell lines Docetaxel Silencing FAK in ovarian carcinoma sensitizes cells to docetaxel [159]
Colorectal carcinoma In vitro—cell lines 5-fluorouracil Silencing FAK in colorectal carcinoma sensitizes the cells to 5-fluorouracil [160]